The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)

Sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology (Industry)
Overall Status
Completed
CT.gov ID
NCT01729949
Collaborator
GlaxoSmithKline (Industry)
34
1
2
66.8
0.5

Study Details

Study Description

Brief Summary

  1. The primary objective is to determine the effect of fruit polyphenols on postprandial lipoprotein triglyceride metabolism after consumption a standard high carbohydrate/fat breakfast meal with a beverage rich in fruit-derived polyphenols compared to energy and macro-/micro-nutrient matched control beverage (acute, Part 1).

  2. Secondary objectives are: 1)to assess the effects of consuming daily for 8 weeks (chronic, Part 2) a beverage rich in fruit polyphenols compared to an energy and macro-/micro- nutrient matched control beverage on fasting glucose, insulin, lipids and markers of oxidative stress; and 2) to assess the effects of these beverages on meal-related changes in metabolic and oxidative stress measures after 8 weeks daily consumption.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Active Treatment Beverage
  • Dietary Supplement: Placebo Treatment Beverage
N/A

Detailed Description

The study is a single-center, double-blinded, randomized, 2-part, 2-arm, 4-sequence, crossover study that incorporates both the acute and chronic evaluations of fruit polyphenols on metabolic indices and markers of oxidative stress.

A planned sample size of 30 overweight men and women will be recruited into the study. Subjects will be required to meet several inclusion and exclusion criteria, which will be assessed through online and clinic screening mechanisms, including questionnaires, blood analysis, and anthropometric measurements. Eligible subjects will be invited to participate in the study. Subjects will begin by completing a 7-day pre-study assessment of their usual dietary intake using 3-day food diary followed by washout of dietary polyphenols. Subjects will participate in 4, 6 h postprandial study days: 2 preceding the chronic intervention and 2 after 8 weeks each of active (fruit polyphenols) and placebo beverages. Subjects will be randomized on the first day of starting the acute and chronic study phases. Subjects will be asked to limit polyphenolic containing foods and beverages for 3 days prior to each 6 h postprandial study visit as well through the chronic dietary intervention. Subjects will be provided a standardized dinner meal pack on the day before each 6 h postprandial visit.

For each 6 h postprandial study visit, subjects will arrive fasted and follow procedures published by our lab previously. This includes: pre-study evaluation for compliance (fasting, dinner consumption, limited polyphenol intake) and readiness for study visit, catheter placement by registered nurse, fasting blood sample, consumption of high fat/carbohydrate meal accompanied by 1 of the two treatment beverages (active/fruit polyphenol or placebo beverage), subsequent blood sampling from catheter [ ~1 tablespoon (12ml)] at designated time points for 6 hours. Each postprandial study visit day will last approximately 7 hours and subjects will be required to remain at the Clinical Nutrition Research Center at the Illinois Institute of Technology main campus for the duration of the visit. The visit procedures are repeated twice ~ 1 week apart to accommodate subject testing with both beverages.

After completing both acute 6 h postprandial study visits, subjects will roll over to the chronic phase of the study and receive a 2nd randomization sequence for consuming the active or the placebo beverage daily for 8 weeks. Before crossing over to the alternative treatment beverage for another 8 weeks, subjects will have a 4-week break (wash out). Subjects will be counseled for a low polyphenolic diet throughout the study to consume the assigned beverage twice per day with lunch and evening meals (except during 4-week washout).

At the end of each week 8 treatment period, subjects will come to the research center for a 6 h postprandial study visit day: all procedures are identical on each postprandial study test visit with the exception that only the placebo beverage will be consumed with the breakfast.

Study Design

Study Type:
Interventional
Actual Enrollment :
34 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)
Actual Study Start Date :
Dec 1, 2012
Actual Primary Completion Date :
Mar 20, 2014
Actual Study Completion Date :
Jun 26, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active Treatment Beverage

Strawberry powder and Blackcurrent extract

Dietary Supplement: Active Treatment Beverage
Strawberry and Blackcurrent extract
Other Names:
  • Active Comparator
  • Placebo Comparator: Placebo Treatment Beverage

    Placebo Beverage

    Dietary Supplement: Placebo Treatment Beverage
    without active components
    Other Names:
  • Placebo Comparator
  • Outcome Measures

    Primary Outcome Measures

    1. Changes in Plasma Triglycerides Concentrations [Acute Postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)]

      Changes in Plasma Triglyceride concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC

    Secondary Outcome Measures

    1. Changes in Plasma Lipid and Lipoprotein panels [Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)]

      Changes in Lipids (panel) and lipoprotein particle size/density by nuclear magnetic resonance (NMR)

    2. Changes in insulin concentrations [Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)]

      Changes in Plasma insulin concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax

    3. Changes in LDL oxidation [Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)]

      Changes in Plasma OxLDL concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, and Cmax

    4. Changes in F2-isoprostane concentrations [Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h)]

      Changes in Plasma F2-isoprostane concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phases assessed by iAUC, total AUC, Cmax and TMax

    Other Outcome Measures

    1. Changes in plasma glucose concentrations [Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).]

      Changes in Plasma glucose concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax

    2. Changes in polyphenol anthocyanin concentrations [Acute postprandial (6 h) and chronic (8 week) fasting and postprandial (6 h).]

      Changes in Plasma polyphenol anthocyanin concentrations during the acute phases (from 0 to 6 hrs) and over the chronic phase, assessed by iAUC, total AUC, Cmax and TMax

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Non-smoking healthy overweight or class I obesity adult men and women

    • Age 40-65yr

    • Weight stable

    • Able to provide informed consent

    • Able to comply and perform the procedures requested by the protocol.

    Exclusion Criteria:
    • Smokers or recent past smokers

    • Men or women with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients

    • Diabetes

    • Fasting blood glucose concentrations >125 mg/dL

    • Fasting Total Cholesterol >250 mg/dL (6.47mmol/L)

    • Fasting Triglycerides >250 mg/dL (2.82 mmol/L)

    • Fasting LDL cholesterol >180 mg/dL (4.66 mmol/L)

    • Uncontrolled blood pressure >140 mmHg/90 mmHg

    • Documented vascular disease

    • Cancer other than skin (non-melanoma) in previous 5 years

    • Lactating and/or pregnant

    • Taking medications or dietary supplements eg., antioxidant supplements, lipid lowering medication, blood pressure lowering medications.

    • Recent blood donors (within 3 months)

    • Vegans

    • Substance (alcohol or drug) abuser (within the last 2 years)

    • Participated in a chronic feeding or medication clinical trial in the last 3 months.

    • Excessive coffee and tea consumers (> 4 cups/d)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Clinical Nutrition Research Center Chicago Illinois United States 60616

    Sponsors and Collaborators

    • Clinical Nutrition Research Center, Illinois Institute of Technology
    • GlaxoSmithKline

    Investigators

    • Principal Investigator: Britt Burton-Freeman, Ph.D, Illinois Institute of Technology
    • Study Chair: Indika Edirisinghe, Ph.D, Illinois Instutute of Technology

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Clinical Nutrition Research Center, Illinois Institute of Technology
    ClinicalTrials.gov Identifier:
    NCT01729949
    Other Study ID Numbers:
    • PPF 2012-073
    First Posted:
    Nov 21, 2012
    Last Update Posted:
    Jul 27, 2021
    Last Verified:
    Jul 1, 2021
    Keywords provided by Clinical Nutrition Research Center, Illinois Institute of Technology
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 27, 2021